Kenneth B. Lee's most recent trade in Biocryst Pharmaceuticals Inc. was a trade of 39,072 Automatic Stock Option Grant done . Disclosure was reported to the exchange on June 13, 2023.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Biocryst Pharmaceuticals Inc. | Kenneth B. Lee | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2023 | 39,072 | 39,072 | - | - | Automatic Stock Option Grant | |
| Biocryst Pharmaceuticals Inc. | Kenneth B. Lee | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2023 | 16,745 | 68,863 (0%) | 0% | 0 | Common Stock | |
| Biocryst Pharmaceuticals Inc. | Kenneth B. Lee | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2023 | 15,000 | 0 | - | - | Automatic Stock Option Grant | |
| Biocryst Pharmaceuticals Inc. | Kenneth B. Lee | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.71 per share. | 31 Jan 2023 | 15,000 | 52,118 (0%) | 0% | 1.7 | 25,650 | Common Stock |
| Eyenovia Inc | Kenneth B. Lee | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2022 | 30,769 | 30,769 | - | - | Stock Option (right to buy) | |
| Eyenovia Inc | Kenneth B. Lee | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2022 | 22,222 | 64,544 (0%) | 0% | 0 | Common Stock, par value $.0001 | |
| Biocryst Pharmaceuticals Inc. | Kenneth B. Lee | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2022 | 30,022 | 30,022 | - | - | Automatic Stock Option Grant | |
| Biocryst Pharmaceuticals Inc. | Kenneth B. Lee | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2022 | 12,866 | 37,118 (0%) | 0% | 0 | Common Stock | |
| Eyenovia Inc | Kenneth B. Lee | Director | Purchase of securities on an exchange or from another person at price $ 2.20 per share. | 19 May 2022 | 10,000 | 42,322 (0%) | 0% | 2.2 | 22,000 | Common Stock, par value $.0001 |
| Eyenovia Inc | Kenneth B. Lee | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Nov 2021 | 9,653 | 9,653 | - | - | Stock Option (right to buy) | |
| Eyenovia Inc | Kenneth B. Lee | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Nov 2021 | 6,963 | 32,322 (0%) | 0% | 0 | Common Stock, par value $.0001 | |
| Biocryst Pharmaceuticals Inc. | Kenneth B. Lee | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Sep 2021 | 15,000 | 0 | - | - | Automatic Stock Option Grant | |
| Biocryst Pharmaceuticals Inc. | Kenneth B. Lee | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.22 per share. | 13 Sep 2021 | 15,000 | 30,252 (0%) | 0% | 3.2 | 48,300 | Common Stock |
| Biocryst Pharmaceuticals Inc. | Kenneth B. Lee | Director | Sale of securities on an exchange or to another person at price $ 15.35 per share. | 13 Sep 2021 | 6,000 | 24,252 (0%) | 0% | 15.4 | 92,100 | Common Stock |
| Biocryst Pharmaceuticals Inc. | Kenneth B. Lee | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 May 2021 | 40,000 | 40,000 | - | - | Automatic Stock Option Grant | |
| Eyenovia Inc | Kenneth B. Lee | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Sep 2020 | 9,820 | 9,820 | - | - | Stock Option (right to buy) | |
| Eyenovia Inc | Kenneth B. Lee | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Sep 2020 | 7,288 | 19,359 (0%) | 0% | 0 | Common Stock, par value $.0001 |